News & Press

NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares are being offered by Lucid. The gross proceeds to Lucid from the offering, before deducting underwriting discounts, commissions and other offering expenses payable by Lucid, are expected to be $70,000,000. In addition, Lucid has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Lucid at the initial public offering price less underwriting discounts and commissions.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that prominent global industry executive Aster Angagaw has joined the Board of Directors of its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”). Ms. Angagaw will serve on the Company’s Audit and Nominating Committees.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (“Lucid”), has completed European IVDD CE Mark certification of its EsoGuard® Esophageal DNA Test (“EsoGuard”).

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a highly differentiated, multi-product, commercial-stage medical technology company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), announced today that David Poppers, M.D. Ph.D. will be presenting data on his team’s initial experience using Lucid’s EsoCheck® Esophageal Cell Collection Device and EsoGuard® Esophageal DNA Test at the upcoming Digestive Disease Week 2021 medical conference, which will be held virtually May 21-23, 2021.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (“Lucid”) and Solys Diagnostics Inc. (“Solys”), discussed preliminary financial results for the three and 12 months ended December 31, 2020 and made two strategic announcements regarding Lucid and its EsoGuard® product.

“Following a strong fourth quarter of 2020 and start of 2021, including raising over $30 million from institutional investors, we find ourselves in the strongest financial position in our history and with the confidence and determination necessary to rapidly and effectively advance and expand our mission,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “In addition to providing an update on all areas of our business, we are making two important announcements regarding Lucid and EsoGuard consistent with that sentiment.”

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multiproduct medical device company, today announced that the EsoCheck Esophageal Cell Collection Device with Collect+Protect Technology, developed and marketed by its majority owned subsidiary Lucid Diagnostics Inc. (Lucid), was named a Silver winner of the 2020 Edison Best New Product Awards in the Medical/Dental category and Testing Solutions subcategory.

​


“After a thorough review, the Edison Awards judges recognize EsoCheck as a game changing innovation standing out among the best new products and services launched in their category”, said Frank Bonafilia, Executive Director of the Edison Awards.

Disposable single-use device designed to provide safer, more efficient and cost-effective ablation of dysplastic Barrett’s Esophagus, complementing Lucid Diagnostics’ EsoGuard™ and EsoCheck™ products.

​

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has added the EsoCure™ Esophageal Ablation Device with Caldus™ Technology to its commercial product pipeline.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and nine months ended September 30, 2019 and provided a business update.

​

“The third quarter and recent weeks have been highly productive as we secured financing on favorable terms and approach exciting upcoming milestones which include the commercial launch of EsoGuard,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer.

“The first quarter and recent weeks have been perhaps the most exciting period in PAVmed’s history, anchored by a long-anticipated major clinical milestone for our leading product, multiple technological breakthroughs across our portfolio and several key patent allowances,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. 

 PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of a 510(k) premarket notification submission for the EsoCheck™ Cell Collection Device (CCD) which its subsidiary Lucid Diagnostics filed on November 21, 2018. 

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its majority-owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), announced yesterday that Lucid has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Lucid Diagnostics intends to list its common stock on The Nasdaq Stock Market under the ticker symbol "LUCD.”

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that medical diagnostics pioneer Stanley N. Lapidus, founder and former Chairman and CEO of Exact Sciences (Nasdaq: EXAS), has joined its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”) as Vice Chairman of Lucid’s Board of Directors.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that Lucid’s EsoCheck® Esophageal Cell Collection Device with Collect+Protect™ technology (“EsoCheck”) has received CE Mark certification.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid” or the “Company”) has substantially expanded its commercial leadership team, adding four senior industry veterans to support one pillar of its growth strategy focused on expanding commercialization of its EsoGuard® Esophageal DNA Test across multiple channels.

​

“Shaun O’Neil, our Chief Commercial Officer, and I are delighted to welcome four new members of our commercial leadership team,” said Lishan Aklog M.D., Lucid’s Executive Chairman and PAVmed’s Chairman and Chief Executive Officer.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that medical diagnostics pioneer Stanley Lapidus, founder and former Chairman and CEO of Exact Sciences (Nasdaq: EXAS), has joined its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), as a Strategic Advisor to assist with its commercial, regulatory, clinical trial and capital markets strategies.

​

“I am thrilled to welcome Stan Lapidus as a Lucid Strategic Advisor and look forward to tapping into his vast wealth of knowledge, experience and wisdom as we advance EsoGuard and EsoCheck commercialization,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer and Lucid’s Executive Chairman.

Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and frequent invasive endoscopies

NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has entered into a clinical trial research agreement with the University of

Pennsylvania (“Penn”) for a clinical trial designed to evaluate whether Lucid’s EsoCheck™ Esophageal Cell

Collection Device with Collect+Protect™ Technology (“EsoCheck”) provides a less invasive, more efficient, and costeffective

alternative to endoscopic biopsies in the management of patients with Eosinophilic Esophagitis.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company’s majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its EsoGuard™ Esophageal DNA Test on esophageal samples collected using its EsoCheck™ Cell Collection Device in a prevalent well-defined group of patients at elevated risk for esophageal dysplasia due to chronic

gastroesophageal reflux disease (GERD).

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and six months ended June 30, 2019 and provided a

business update.

​

“The second quarter and early third quarter has been a period of solid progress for PAVmed,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “We advanced our lead product portfolio on multiple fronts, including the recent successful completion of all procedures in the CarpX™ clinical safety study. This progress has set up the remainder of the year to be an exciting period of major milestones, including the full U.S. commercial launch of EsoGuard™ and the upcoming FDA 510(k) re-submission of CarpX.”

 PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and 12 months ended December 31, 2018 and provided a business update. 

​

“I am very pleased with the progress PAVmed has made during what has been a very active and productive fourth quarter of 2018 and in recent months,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “We have achieved several important milestones across our lead product ...

PAVmed subsidiary Lucid Diagnostics Inc. secures exclusive worldwide license for EsoCheck

​

Rapid, highly accurate, office-based test utilizes a novel, non-invasive

cell-sampling device coupled with proprietary DNA biomarkers to

detect Barrett’s Esophagus, precursor to the most common and lethal form of esophageal cancer, caused by acid reflux

​

First commercial product projected to launch in the U.S. in the first

quarter of 2019, eventually targeting up to 50 million at-risk patients

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”) has begun testing patients referred by primary care physicians (“PCPs”) at three Lucid Test Centers in the Phoenix metropolitan area. Patients with chronic heartburn, also known as gastroesophageal reflux disease (“GERD”), who are referred to the centers undergo a rapid non-invasive office procedure, performed by Lucid-employed clinical personnel, using Lucid’s EsoCheck® Cell Collection Device (“EsoCheck”) to collect surface esophageal cells for its EsoGuard® Esophageal Test (“EsoGuard”).

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid”) has entered into a definitive agreement with UpScriptHealth (“UpScript”), a leading, nationwide, direct-to-consumer telemedicine company. Pursuant to the agreement, UpScript will support Lucid’s upcoming EsoGuard Telemedicine Program by providing a Lucid-branded web-based telemedicine platform for patients with chronic heartburn symptoms to request video evaluation by a physician and, if clinically indicated, referral for Lucid’s EsoGuard® Esophageal DNA Test (“EsoGuard”).

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that David M. Poppers, M.D. Ph.D., Clinical Professor, Division of Gastroenterology and Hepatology at NYU Grossman School of Medicine, presented data on his team’s initial experience using Lucid’s EsoCheck® Esophageal Cell Collection Device with Collect+Protect™ technology (“EsoCheck”) and EsoGuard® Esophageal DNA Test (“EsoGuard”) at the Digestive Disease Week 2021 medical conference, in a presentation entitled EsoCheck/EsoGuard: A Novel, Simple, Outpatient Technology for the Early Detection of Esophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid” or the “Company”) has appointed nationally recognized healthcare executive Jacque J. Sokolov to its Board of Directors (the “Board”). Dr. Sokolov will help establish and serve as the inaugural Chair of the Board’s new Compliance & Quality Committee. He will also serve on Lucid’s Audit and Compensation Committees.

​

“I am delighted to welcome Jacque Sokolov to Lucid’s Board of Directors,” said Lishan Aklog M.D., Lucid’s Executive Chairman and PAVmed’s Chairman and Chief Executive Officer. “Jacque brings remarkable breadth of experience and expertise across all aspects of the healthcare industry including as public and private company director, investor and strategic consultant in healthcare delivery, regulatory compliance & quality and biotechnology.”

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), received preliminary gapfill payment determination for its EsoGuard Esophageal DNA Test (“EsoGuard”).

On June 9, 2020, the U.S. Center for Medicare and Medicare Services (“CMS”) published its “CY 2020 - Clinical Laboratory Fee Schedule Test Codes Preliminary Determinations” listing preliminary gapfill payment recommendations for the current review cycle. Medicare Administrative Contractor (MAC) Palmetto GBA recommended EsoGuard CPT code 0114U payment of $1,938.01 in 38 states and $2,690 in 12 states (including Florida, New Jersey and Pennsylvania) and two U.S. territories.

Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer develops.

NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has entered into a sponsored research agreement with the Fred Hutchinson Cancer Research Center (“Fred Hutchinson”) at the University of Washington in Seattle, WA to evaluate Barrett’s Esophagus (BE) progression biomarkers in patients using Lucid’s EsoCheck™ Esophageal Cell Collection Device with Collect+Protect™ Technology.

First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer

First patients to undergo testing today at gastroenterology center of excellence.

​

NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”) has launched its EsoGuardTM Esophageal DNA Test as a Laboratory Developed Test (LDT), after completing CLIA/CAP certification of the test at Lucid’s commercial diagnostic laboratory partner ResearchDx Inc. dba Pacific Dx (“ResearchDx”), headquartered in Irvine, CA. EsoGuard is the first such DNA test designed to facilitate the diagnosis of Barrett’s Esophagus (BE) and related precursors to highly lethal esophageal adenocarcinoma (EAC).

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received 510(k) marketing clearance for its EsoCheck Cell Collection Device™ (“EsoCheck”) from the U.S. Food and Drug Administration (FDA). 

​

“I have spent my career seeking to improve the care of patients with gastroesophageal reflux disease and Barrett’s Esophagus and to prevent deaths from esophageal cancer. I have actively participated in the development of key advances..."

 PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its subsidiary, Lucid Diagnostics Inc. (“Lucid”), has launched a world-class medical advisory board (MAB) consisting of internationally renowned experts in gastroesophageal reflux disease (GERD), Barrett’s Esophagus (BE) and esophageal cancer and has appointed veteran life sciences industry executive David Wurtman, MD, MBA, as its Chief Medical Officer. 

PAVmed subsidiary to receive exclusive worldwide license to commercialize EsoCheck

Five-minute, office-based alternative to endoscopy utilizes highly accurate DNA biomarkers to detect Barrett’s Esophagus, the precursor to a common highly lethal form of esophageal cancer

​

Will target up to 50 million at-risk patients and an estimated addressable market of several billion dollars